Log In
BCIQ
Print this Print this
 

Semprana, dihydroergotamine (formerly Levadex, MAP0004)

  Manage Alerts
Collapse Summary General Information
Company Allergan plc
DescriptionDihydroergotamine (DHE) mesylate compound that agonizes the serotonin (5-HT) receptor and is delivered via Map's Tempo Inhaler
Molecular Target Serotonin (5-HT1D) receptor
Mechanism of ActionSerotonin (5-HT1D) receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationMigraine
Indication DetailsTreat acute migraine; Treat acute migraine in patients with compromised lung function
Regulatory Designation U.S. - Undisclosed Review (Treat acute migraine)
PartnerNektar Therapeutics

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$1,118.0M

$1,021.0M

$97.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/11/2013

$961.0M

$961.0M

0

01/31/2011

$157.0M

$60.0M

$97.0M

Get a free BioCentury trial today